Liv.52 vs Udiliv 300 (Ursodeoxycholic Acid): Herbal Liver Care vs Gallstone Dissolution
Clinical comparison between Ayurvedic Liv.52 and allopathic Udiliv 300 (Ursodeoxycholic Acid): bile acid dissolution, cholesterol gallstones, fatty...
Liv.52 is an Ayurvedic herbal supplement (Himsra, Kasani) used for general liver health, mild fatty liver, and appetite stimulation. Udiliv 300 is a potent prescription allopathic medicine containing Ursodeoxycholic Acid (UDCA 300mg), a naturally occurring bile acid that actively dissolves small cholesterol gallstones, protects liver cells in primary biliary cholangitis, and treats intrahepatic cholestasis in pregnancy.
1. The Bile Acid Chemistry of Udiliv 300
Ursodeoxycholic acid replaces toxic, hydrophobic endogenous bile acids in the enterohepatic circulation with hydrophilic, non-toxic UDCA. It disperses cholesterol in micellar liquid form, dissolving radiolucent cholesterol gallstones without surgery.
2. Supportive Herbal Protection in Liv.52
Liv.52 acts as a mild botanical antioxidant that protects hepatocyte membranes and enhances detoxifying enzyme pathways. However, it CANNOT dissolve gallstones or treat autoimmune liver cholestasis.
3. Generic Pricing
Branded Udiliv 300 is expensive (~₹480 to ₹550 for 15 tablets). Bioequivalent Ursodeoxycholic Acid 300mg tablets at Jan Aushadhi cost approximately ₹120 for 10 tablets (75% savings).
Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison
Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.
| Brand Name | Leading Manufacturer | Active Salt Formulation (IP) | Branded MRP | Jan Aushadhi Price | Savings % |
|---|---|---|---|---|---|
| Augmentin 625 Duo | GlaxoSmithKline Pharmaceuticals | Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP | ₹220.00 | ₹58.00 | 74% |
| Dolo 650 | Micro Labs Ltd | Paracetamol (Acetaminophen) 650mg IP | ₹34.00 | ₹5.50 | 84% |
| Pantocid 40 | Sun Pharmaceutical Industries | Pantoprazole Sodium 40mg IP (Gastro-resistant) | ₹155.00 | ₹8.00 | 95% |
| Azithral 500 | Alembic Pharmaceuticals | Azithromycin Dihydrate 500mg IP | ₹132.00 | ₹24.00 | 82% |
| Glycomet 500 | USV Private Limited | Metformin Hydrochloride 500mg IP | ₹24.00 | ₹4.50 | 81% |
| Shelcal 500 | Torrent Pharmaceuticals | Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP | ₹134.00 | ₹16.00 | 88% |
| Telma 40 | Glenmark Pharmaceuticals | Telmisartan 40mg IP | ₹92.00 | ₹7.50 | 92% |
| Montair-LC | Cipla Ltd | Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP | ₹210.00 | ₹18.00 | 91% |
| Combined 8-Drug Essential Therapy Basket Total: | ₹1,001.00 | ₹141.00 | 85.9% Net Savings | ||
Frequently Asked Questions (Clinical & Regulatory)
Q1: Can Udiliv 300 dissolve calcified gallstones?
No. UDCA only dissolves small, non-calcified, purely radiolucent cholesterol gallstones (typically <15mm). Calcified stones visible on X-ray require surgical cholecystectomy.
Q2: Is Udiliv 300 safe during pregnancy for severe itching (ICP)?
Yes, UDCA is the first-line evidence-based clinical treatment for Intrahepatic Cholestasis of Pregnancy (ICP) to lower maternal bile acids and protect the fetus.
Q3: How does the CDSCO define bioequivalence when comparing two pharmaceutical formulations?
Bioequivalence is confirmed when two pharmaceutical products contain identical active therapeutic moieties and show no statistically significant difference in Cmax and AUC under single-dose fasting and fed pharmacokinetic studies within the 80% to 125% confidence interval.
Q4: When comparing two drugs in the same clinical class, what determines superior therapeutic choice?
Therapeutic selection depends on receptor selectivity, onset speed, elimination half-life, clearance pathway (hepatic CYP450 vs renal excretion), drug interaction liability, and clinical trial evidence regarding organ-specific outcomes.
Q5: Can patients interchange two bioequivalent branded formulations without loss of efficacy?
Yes. Formulations produced under Schedule M Good Manufacturing Practices containing identical active pharmaceutical salts and dissolution profiles can be interchanged safely under pharmacist guidance.
This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.
Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.